Corifact
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Corifact
- Generic name
- FACTOR XIII CONCENTRATE (HUMAN)
- Manufacturer
- CSL Behring GmbH
- Product type
- PLASMA DERIVATIVE
- SPL set ID
- 96f1b658-01b0-43a7-9aba-693271389a78
- SPL ID
- 5834bcd0-b7c1-4591-8ec7-f0c847c5e428
- Version
- 14
- Effective date
- 2020-08-18
- Source export date
- 2026-11-13
- Source partition
- 8
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0008-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/5b373538593b900129b6789b4289137dca62e689b6d06cab0e8e33844e7e2588/drug-label-0008-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 16:55:24
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | BLA | 125385 | derived:openfda.application_number |
| application number | BLA125385 | openfda.application_number | |
| brand name | Corifact | openfda.brand_name | |
| generic name | FACTOR XIII CONCENTRATE (HUMAN) | openfda.generic_name | |
| manufacturer name | CSL Behring GmbH | openfda.manufacturer_name | |
| ndc | package | 63833-734-65 | openfda.package_ndc |
| ndc | package | 63833-518-02 | openfda.package_ndc |
| ndc | package | 63833-528-01 | openfda.package_ndc |
| ndc | product | 63833-518 | openfda.product_ndc |
| ndc11 | package | 63833051802 | derived:openfda.package_ndc |
| ndc11 | package | 63833052801 | derived:openfda.package_ndc |
| ndc11 | package | 63833073465 | derived:openfda.package_ndc |
| rxcui | 1095281 | openfda.rxcui | |
| rxcui | 1095283 | openfda.rxcui | |
| spl id | 5834bcd0-b7c1-4591-8ec7-f0c847c5e428 | id | |
| spl set id | 96f1b658-01b0-43a7-9aba-693271389a78 | set_id |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
5 WARNINGS AND PRECAUTIONS Hypersensitivity reaction may occur. ( 5.1 ) Inhibitory antibodies have been detected in patients receiving CORIFACT. ( 5.2 ) Thrombotic events have been reported with CORIFACT. ( 5.3 ) Because CORIFACT is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob Disease (CJD) agent. ( 5.4 ) 5.1 Hypersensitivity Hypersensitivity reactions have been observed with CORIFACT. If signs or symptoms of anaphylaxis or hypersensitivity reactions (including urticaria, rash, tightness of the chest, wheezing, hypotension) occur, immediately discontinue administration [see Patient Counseling Information (17) ] and institute appropriate treatment. 5.2 Immunogenicity Development of inhibitory antibodies against FXIII has been detected in patients receiving CORIFACT. Monitor patients for development of inhibitory antibodies. Presence of inhibitory antibodies may manifest as an inadequate response to treatment. If expected plasma FXIII activity levels are not attained, or if breakthrough bleeding occurs while receiving prophylaxis, perform an assay that measures FXIII inhibitory antibody concentrations. 5.3 Thromboembolic Risk Thromboembolic complications have been reported. Monitor patients with known risk factors for thrombotic events. 5.4 Transmission of Infectious Agents Because CORIFACT is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. This also applies to unknown or emerging viruses and other pathogens. All infections thought by a physician to have been possibly transmitted by this product are to be reported by the physician or other healthcare provider to the CSL Behring Pharmacovigilance Department at 1-866-915-6958 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 5.5 Monitoring Laboratory Tests Monitor patient's trough FXIII activity level during treatment with CORIFACT [see Dosage and Administration (2.2) ] . If breakthrough bleeding occurs, or if expected peak plasma FXIII activity levels are not attained, perform an investigation to determine the presence of FXIII inhibitory antibodies [see Clinical Pharmacology (12.3) ] .
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS The most common adverse reactions reported in clinical trials (>1%) are joint inflammation, hypersensitivity, rash, pruritus, erythema, hematoma, arthralgia, headache, elevated thrombin-antithrombin levels, and increased blood lactate dehydrogenase. The serious adverse reactions, reported (frequency 0.5%), were hypersensitivity, acute ischemia, and neutralizing antibodies against FXIII [see Warnings and Precautions 5) ] . The most common adverse reactions reported in clinical trials (>1%) were joint inflammation, hypersensitivity, rash, pruritus, erythema, hematoma, arthralgia, headache, elevated thrombin-antithrombin levels, and increased blood lactate dehydrogenase. ( 6 ) Serious adverse reactions reported in clinical trials were hypersensitivity, acute ischemia, and neutralizing antibodies against FXIII. ( 5.1 , 6 ) To report SUSPECTED ADVERSE REACTIONS, contact the CSL Behring Pharmacovigilance Department at 1-866-915-6958 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Twelve clinical studies included a total of 188 subjects, 108 subjects were <16 years of age [see Use in Specific Populations (8.4) ] and a total of approximately 4314 infusions of CORIFACT were administered in the studies. The most common adverse reactions occurring at a rate of 1-2% are outlined [see Adverse Reactions (6) ] . 6.2 Immunogenicity A case of neutralizing antibodies against FXIII was reported in an open enrollment clinical study. The patient received prophylactic treatment with CORIFACT for ten years. Concomitant medications included interferon for hepatitis C infection. This patient presented with bruising, and post-infusion FXIII levels were found to be lower than expected. Over several weeks, FXIII recovery values decreased, so the dose and frequency of treatments were increased. Neutralizing antibodies to FXIII were detected, interferon treatment was discontinued, and the subject underwent plasmapheresis. Within a month, neutralizing antibodies were no longer detectable, FXIII recovery levels improved, and the previous prophylactic regimen was resumed.
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.